O. Bernard
Université Paris-Saclay
9 Papers
29 Citations
O. Bernard is an academic researcher from Université Paris-Saclay. The author has contributed to research in topics: Myeloid & Chromosomal translocation. The author has an hindex of 8, co-authored 9 publications.
Chat about Author
Papers
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Lynn Quek,Muriel D. David,Alison Kennedy,Marlen Metzner,Michael Amatangelo,Alan Shih,Bilyana Stoilova,Cyril Quivoron,Maël Heiblig,Christophe Willekens,Véronique Saada,Samar Alsafadi,M. S. Vijayabaskar,Andy Peniket,O. Bernard,Sam Agresta,Katharine E. Yen,Kyle J. MacBeth,Eytan M. Stein,George S. Vassiliou,Ross L. Levine,Stéphane de Botton,Anjan Thakurta,Virginie Penard-Lacronique,Paresh Vyas +24 more
TL;DR: Mapping of the clonal structure of bone marrow cells in patients with acute myeloid leukemia treated with the IDH2 inhibitor enasidenib reveals heterogeneity in the cellular differentiation response and in mechanisms of relapse.
DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.
Laurianne Scourzic,Lucile Couronné,Marianne Terndrup Pedersen,V Della Valle,M'Boyba Diop,Elena Mylonas,Julien Calvo,Enguerran Mouly,Cécile K. Lopez,Cécile K. Lopez,Cécile K. Lopez,N Martin,Michaela Fontenay,Ambre Bender,Sylvain Guibert,Patrice Dubreuil,Philippe Dessen,Nathalie Droin,Françoise Pflumio,Michael Weber,P. Gaulard,P. Gaulard,Kristian Helin,Thomas Mercher,Thomas Mercher,Thomas Mercher,O. Bernard +26 more
TL;DR: The data confirm the transformation potential of DNMT3AR882H Tet2−/− progenitors and represent the first cooperative model in mice involving Tet2 inactivation driving lymphoid malignancies.
70
Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies.
Frederik Damm,Frederik Damm,Frederik Damm,Florence Nguyen-Khac,Florence Nguyen-Khac,Michaela Fontenay,O. Bernard +6 more
TL;DR: Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies were reported in this article, showing that spliceosomes are vulnerable to mutations in both chronic and acute leukemia.
30
Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia
Lynn Quek,Muriel D. David,Alan Kennedy,Marlen Metzner,Michael Amatangelo,Alan H. Shih,Bilyana Stoilova,Dimitris Karamitros,Cyril Quivoron,Maël Heiblig,Christophe Willekens,Véronique Saada,Andy Peniket,O. Bernard,Samuel V. Agresta,Katherine Yen,Eytan M. Stein,S. de Botton,S. de Botton,Anjan Thakurta,Ross L. Levine,Virginie Penard-Lacronique,Paresh Vyas +22 more
TL;DR: In this article, the authors used single cell genotyping (SCG) to reveal linear or branching clonal structures in mIDH2 AML patients, and they found that different combinations of co-operating mutations result in functional heterogeneity of mIDHI2 clones.
4
•Journal Article
A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies.
TL;DR: Data from a translocation t(9;14)(p21-p22;q11) in a B-cell type acute lymphoblastic leukemia are consistent with the existence of a new type of p16INK4/MTS1 transcript whose significance is discussed.